(S)-N-[1-(4-Cyclopropylmethyl-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl)-ethyl] -3-(2-fluoro-phenyl)-acrylamide is a potent and efficacious KCNQ2 opener which inhibits induced hyperexcitability of rat hippocampal neurons

Bioorganic and Medicinal Chemistry Letters

Volumn 14, Issue 8, 2004, Pages 1991-1995

  Wu, Yong Jin ^a   Boissard, Christopher G ^a   Chen, Jie ^a   Fitzpatrick, William ^a   Gao, Qi ^a   Gribkoff, Valentin K ^a   Harden, David G ^a   He, Huan ^a   Knox, Ronald J ^a   Natale, Joanne ^a   Pieschl, Rick L ^a   Starrett Jr , John E ^a   Sun, Li Qiang ^a   Thompson, Mark ^a   Weaver, David ^a   Wu, Dedong ^a   Dworetzky, Steven I ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACRYLAMIDE DERIVATIVE; LINOPIRDINE; N [1 (4 CYCLOPROPYLMETHYL 3,4 DIHYDRO 2H BENZ[1,4]OXAZIN 6 YL)ETHYL] 3 (2 FLUOROPHENYL)ACRYLAMIDE; POTASSIUM CHANNEL; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; DRUG ACTIVITY; DRUG EFFICACY; DRUG INHIBITION; DRUG POTENCY; HIPPOCAMPUS; NERVE CELL; NERVE CELL EXCITABILITY; NONHUMAN; RAT;

ACRYLAMIDES; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; HIPPOCAMPUS; HUMANS; KCNQ2 POTASSIUM CHANNEL; KIDNEY; MICE; MOLECULAR STRUCTURE; NEURONS; OXAZINES; PATCH-CLAMP TECHNIQUES; POTASSIUM CHANNELS; POTASSIUM CHANNELS, VOLTAGE-GATED; RATS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 12144288995     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2004.01.069     Document Type: Article

References (12)

1. Rockwood K., Beattie B.L., Eastwood M.R., Feldman H., Mohr E., Pryse-Williams W., Gauthier S. Canadian J. Neurol. Sci. 24:1997;140.
2. Tatulian L., Delmas P., Abogadie F.C., Brown D.A. J. Neurosci. 21:2001;5535.
3. Rundfeldt C., Netzer R. Neurosci. Lett. 282:2000;73.
4. Wickenden A.D., Zou A., Wagoner P.K., Jegla T. Br. J. Pharmacol. 132:2001;381.
5. Blackburn-Munro G., Jensen B.S. Eur. J. Pharmacol. 460:2003;109.
6. Ilyin, V. I.; Carlin, K. P.; Hodges, D. D.; Robledo, S.; Woodward, R. M. Society for Neuroscience 32 nd Annual Meeting, Orlando, Florida, November 2-7, 2002, poster No. 758.10.
7. Wu Y.-J., Boissard C.G., Greco C., Gribkoff V.K., Harden D.G., He H., L'Heureux A., Kang S.H., Kinney G.G., Knox R.J., Natale J., Newton A.E., Lehtinen-Oboma S., Sinz M.W., Sivarao D.V., Starrett J.E. Jr., Sun L.Q., Tertyshnikova S., Thompson M.W., Weaver D., Wong H.S., Zhang L., Dworetzky S.I. J. Med. Chem. 46:2003;3197.
8. Chen X., Wang W. Ann. Rep. Med. Chem. 38:2003;333.
9. 2).
10. Madsen B.W., Yeo G.F. Arch. Biochem. Biophys. 373:2000;429.
11. Yokoo H., Shiraishi S., Kobayashi H., Yanagita T., Minami S., Yamamoto R., Wada A. Br. J. Pharmacol. 131:2000;779.
12. A manuscript describing the structure and activity of the reference compound will be submitted to Bioorg. Med. Chem. Lett.